Compare ADMA Biologics Inc (ADMA) vs AstraZeneca plc (AZN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs AstraZeneca plc — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while AstraZeneca plc trades at $189.95 (market cap $294.08B). The key difference: AstraZeneca plc is far larger — about 138.1× ADMA Biologics Inc's market cap, and AstraZeneca plc pays a 1.64% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | AZN | |
|---|---|---|
Market Cap | $2.13B | $294.08B |
Sector | Health | Health |
52-Week High | $20.38 | $209.48 |
52-Week Low | $7.60 | $137.44 |
Enterprise Value | $2.20B | $320.32B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
AstraZeneca (AZN) trades at $193.12, down 1.04% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, marking a 17.4% profit margin. Recent news highlights strategic collaborations and regulatory approvals for key drugs like Enhertu, reinforcing growth prospects.
AZN presents a favorable outlook with robust earnings growth and a solid pipeline, though valuation multiples like a P/E of 28.64 suggest premium pricing. Risks include competitive pressures and trial outcomes, but analyst consensus leans bullish with 47.5% buy ratings. Institutional interest remains high, supporting potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
